Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) EVP Matthias Alder sold 150,000 shares of Sucampo Pharmaceuticals stock in a transaction dated Monday, November 28th. The shares were sold at an average price of $16.00, for a total value of $2,400,000.00. Following the completion of the sale, the executive vice president now directly owns 29,449 shares in the company, valued at approximately $471,184. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Shares of Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) opened at 16.15 on Tuesday. The company has a market cap of $691.51 million, a PE ratio of 54.56 and a beta of 1.62. Sucampo Pharmaceuticals Inc. has a one year low of $9.59 and a one year high of $18.75. The stock’s 50 day moving average price is $13.49 and its 200-day moving average price is $12.15.
Sucampo Pharmaceuticals (NASDAQ:SCMP) last posted its earnings results on Wednesday, November 9th. The biopharmaceutical company reported $0.28 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.26 by $0.02. Sucampo Pharmaceuticals had a net margin of 6.29% and a return on equity of 44.19%. The company had revenue of $57.90 million for the quarter, compared to analyst estimates of $51.30 million. During the same quarter in the prior year, the business posted $0.16 EPS. The firm’s revenue was up 73.4% compared to the same quarter last year. On average, analysts expect that Sucampo Pharmaceuticals Inc. will post $1.22 EPS for the current year.
Several large investors have recently bought and sold shares of SCMP. BlackRock Fund Advisors raised its stake in Sucampo Pharmaceuticals by 3.1% in the first quarter. BlackRock Fund Advisors now owns 1,630,036 shares of the biopharmaceutical company’s stock worth $17,816,000 after buying an additional 48,420 shares in the last quarter. Quantbot Technologies LP raised its stake in Sucampo Pharmaceuticals by 850.4% in the second quarter. Quantbot Technologies LP now owns 14,903 shares of the biopharmaceutical company’s stock worth $163,000 after buying an additional 13,335 shares in the last quarter. Princeton Alpha Management LP acquired a new stake in Sucampo Pharmaceuticals during the second quarter worth $138,000. Dynamic Technology Lab Private Ltd acquired a new stake in Sucampo Pharmaceuticals during the second quarter worth $207,000. Finally, Boston Partners raised its stake in Sucampo Pharmaceuticals by 36.6% in the second quarter. Boston Partners now owns 238,519 shares of the biopharmaceutical company’s stock worth $2,617,000 after buying an additional 63,965 shares in the last quarter. Institutional investors own 41.12% of the company’s stock.
A number of research firms recently issued reports on SCMP. Jefferies Group reaffirmed a “hold” rating and issued a $16.00 target price (up previously from $14.00) on shares of Sucampo Pharmaceuticals in a research report on Friday, November 11th. Maxim Group reduced their price target on Sucampo Pharmaceuticals from $26.00 to $17.00 and set a “buy” rating for the company in a report on Monday, August 1st. Zacks Investment Research upgraded Sucampo Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, August 8th. Mizuho cut Sucampo Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $13.00 price target for the company. in a report on Thursday, August 4th. Finally, Vetr cut Sucampo Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $14.00 price target for the company. in a report on Monday, September 19th. Five analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. Sucampo Pharmaceuticals has an average rating of “Buy” and an average price target of $17.33.
About Sucampo Pharmaceuticals